A randomized phase II study of perioperable tiotropium treatment in gastric cancer patient with chronic obstructive pulmonary disease

A randomized phase II study of perioperable tiotropium treatment in gastric cancer patient with chronic obstructive pulmonary disease - A randomized phase II study of tiotropium in gastric cancer with COPD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004496

Enrollment

Registered

2010-11-02

Start date

2010-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer patient with COPD

Interventions

preoperative tiotropium for over 1 week and postoperative tiotropium for 2 weeks Inharation of bromhexine/tyloxapol after surgery

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) histopathologically confirmed gastric cancer. 2) COPD patient, COPD stage I/II 3) no severe heart failure and arrithmia 4) preoperative day > 2 weeks 5) age of 20 years or older 6) Written informed consent

Exclusion criteria

Exclusion criteria: 1) glaucoma 2) dysuria dur to BPH 3) allergy for atropine and tiotropium 4) Patient is diagnosis as asthma 5) clinically important infection or acute inflammation 6) psychological disease 7) patients who are judged to be ineligible by principal investigator for any other reason

Design outcomes

Primary

Measure	Time frame
reduction of FEV1.0 on POD14	—

Secondary

Measure	Time frame
pulmonaly mobidity rate, the number of days for O2 support after surgery	—

Countries

Japan

Contacts

Public ContactSachio Fushida

Kanazawa University Hospital Gastroenterologic Surgery

fushida@staff.kanazawa-u.ac.jp076-265-2362

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026